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ABSTRACT 
Objective: The Remission Evaluation and Mood Inventory Tool (REMIT) was developed as a 
brief complementary measure to provide a more robust assessment of depression improvement 
than tracking DSM-V symptom improvement alone. This study provides further validation of the 
REMIT tool and examines its utility in predicting depression improvement. 
Methods: The sample comprised 294 primary care patients enrolled in a telecare trial of pain 
plus depression and/or anxiety. Assessments collected included: REMIT, PHQ-9 and measures 
assessing anxiety, pain, sleep, fatigue, somatization, health-related quality of life and disability. 
Data was analyzed to assess the REMIT’s validity, its minimally important difference (MID), and 
its utility in predicting 6-month depression improvement. 
Results: Convergent and construct validity of REMIT was supported by moderate correlations 
with mental health measures and weaker correlation with physical health measures. MID of 
approximately 2 points for REMIT was estimated by two metrics: 0.5 standard deviation and 1 
standard error of measurement. Both baseline and 3-month change in REMIT scores predicted 
depression improvement at 6 months. Indeed, REMIT was as good or better predictor than the 
PHQ-9. 
Conclusion: The REMIT measure is a brief 5-item tool that augments core DSM-V symptom-
oriented metrics in assessing and predicting recovery from major depression.      
KEY WORDS 
Depression, Measurement-Based Care, Recovery, Remission, Remission Evaluation and Mood 
Inventory Tool (REMIT) 
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1. INTRODUCTION 
Depression is a common clinical problem, with a prevalence of up to 20% in the 
community (1). It is the most common mental disorder in both primary care and mental health 
specialty settings and the leading cause of disability among all diseases(2, 3). Despite the 
clinical and public health impact of depression, the guidelines for what constitutes successful 
treatment can be difficult to define. Many have advocated a “treat to remission” approach, 
wherein clinicians adjust treatment until patients reach certain thresholds, often defined as 
scoring 7 or less on the Hamilton Rating Scale for Depression (HRSD-17) or below 5 on the 
Patient Health Questionnaire-9 (PHQ-9)(4, 5). Unfortunately, this approach can lead to both 
under and over-treatment. Since all measures have imperfect sensitivity and specificity, false 
positives and false negatives are expected for any cut-point chosen. Unlike patients in clinical 
trials, real-world patients often have significant medical comorbidities which can cause 
impairments in sleep, appetite, energy, and concentration, resulting in persistent elevation in 
these assessment domains. On the other hand, Zimmerman et al. have found that a significant 
proportion of patients who meet criteria for remission as defined by HRSD-17 scores <7 do not 
consider themselves in remission(6). This suggests that there may be aspects of recovery from 
illness not captured by assessing only the core features of DSM-defined major depressive 
disorder. 
 These observations led to the development of the Remission Evaluation and Mood 
Inventory Tool (REMIT), a 5-item self-administered questionnaire which measures aspects of 
depression recovery not captured using core-symptom focused tools such as the PHQ-9 or 
HRSD-17(7).  The REMIT items are more focused on positive psychology constructs such as 
happiness, contentment, emotional regulation, resilience, and hope. This tool performed well in 
a cross-sectional study, with clearly distinct psychometric properties from the PHQ-8, 
demonstrating promise as a tool that might complement existing measures to give a more 
robust account of depression recovery(7). To date, the REMIT has been studied in two samples. 
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One of these was a cross-sectional study(7, 8) and the other had very short-term longitudinal 
follow-up of only 4 weeks(9). Hence, the value of REMIT in predicting depression remission or 
providing a more robust account of depression recovery over more clinically-relevant time spans 
has not yet been investigated. 
 In this study, we postulate that the REMIT tool may complement a measure of DSM-V 
symptoms (the PHQ-9) in predicting improvement in major depression and patient-reported 
recovery. We hypothesized that patients with lower REMIT scores at baseline and greater 
reduction in REMIT scores by 3 months might be more likely to experience depression 
improvement by 6 months compared to patients with higher baseline REMIT scores and less 
change at 3 months.   
 
2. METHODS 
2.1 Study Participants 
This study utilized data collected for the CAM Ps trial, detailed previously(10). Briefly, 
participants were recruited from five primary care clinics at a large VA Medical Center, and 
randomized to two levels of telecare intervention for pain and mood symptoms in a 12-month 
pragmatic trial. The less intensive treatment arm received automated symptom monitoring plus 
web-based self-management, while the more intensive arm received the same interventions 
plus telephone-based treatment monitoring and adjustment by a nurse care manager-physician 
specialist team. Eligibility criteria included age ≥ 18 years old and clinically significant 
musculoskeletal pain plus psychiatric comorbidity. Pain had to be moderate in severity as 
assessed by the brief pain inventory (BPI) and present at least 3 months despite analgesic 
treatment. Psychiatric comorbidity was defined as depression or anxiety of at least moderate 
severity with either: (1) a score of 10 or greater on the PHQ-8 with anhedonia and/or depressed 
mood endorsed; (2) a score of 10 or greater on the GAD-7; or (3) a combined PHQ-8 and GAD-
7 score of at least 12. The PHQ-8 was used for eligibility determination since it omits the item 
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about self-harm yet has scoring thresholds identical to the PHQ-9(11, 12). Exclusion criteria 
included: not speaking English; moderately severe cognitive impairment; suicidality, 
schizophrenia, bipolar disorder, or another severe or complex mental illness not suitable for 
telecare; being pregnant; or an anticipated life expectancy of less than 12 months. 
2.2 Study Measures 
2.2.1 Measure Administration 
Measures to assess depression, anxiety, pain, health-related quality of life, disability, 
medical co-morbidity, and global impression of change were collected at baseline and at defined 
time points during the CAMMPS trial(10). All measures were administered by a research 
interviewer: in person at baseline and over the phone for follow-up time points.  
2.2.2 Depression Measures 
The Patient Health Questionnaire 9-item depression scale (PHQ-9) is a self-
administered 9-item questionnaire wherein patients rate whether they have experienced each of 
the described symptoms “not at all”, “several days”, “more than half the days” or “nearly every 
day” over the preceding two weeks(13). Scores per item range from 0 – 3, with higher scores 
indicating more severe symptoms, and a total score range of 0 – 27. Using the PHQ-9, a patient 
would meet DSM-V criteria for major depression (MD) if they endorsed at least 5 of 9 items as 
present for more than half of the past 14 days and one item must be depressed mood or 
anhedonia. This diagnostic algorithm was used to determine the presence or absence of MD in 
this study.  
The Remission Evaluation and Mood Inventory Tool (REMIT) is a 5-item self-
administered questionnaire that was developed to measure aspects of recovery from 
depression not captured using core-symptom focused tools such as the PHQ-9(7). Patients are 
asked to rate whether - over the past two weeks - they felt happy, content, in control of 
emotions, bounced back when things went wrong or whether the future seemed dark (the latter 
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item is reverse-scored). Choices include “none of the time”, “a little of the time”, “some of the 
time”, “most of the time” and “all of the time”. The scores for each item range from 0 – 4, with a 
possible total score range of 0 – 20 and higher scores reflecting worse severity.  
2.2.3 Other Measures 
The Generalized Anxiety Disorder Scale (GAD-7) is a 7-item self-administered 
questionnaire that assesses the severity of anxiety experienced over the past two weeks. 
Scores range from 0 to 21, with higher scores reflecting greater levels of anxiety(14). 
The Patient Reported Outcomes Measurement Information System (PROMIS) includes a variety 
of measures to evaluate physical and mental health(15, 16). The 8-item scales for anxiety and 
depression from the PROMIS-57 profile were collected, along with the 4-item scales for 
assessing sleep and fatigue from the PROMIS-29 profile. Raw scores are standardized to a T-
score for which the general population mean is 50 with standard deviation of 10; higher scores 
reflect more severe symptoms.  
The Brief Pain Inventory (BPI) is an 11-item self-administered instrument that assesses 
pain severity (4 items) and pain interference (7 items)(17). Each item is scored from 0 to 10 and 
total BPI score is the mean of the 11 items with higher scores representing worse pain.  
The Patient Health Questionnaire somatic symptom scale (PHQ-15) assesses the 
severity of 15 common somatic symptoms. The PHQ-14 is a modified version of this scale in 
which the sexual dysfunction question is omitted(18). PHQ-14 scores range from 0 – 28, with 
higher scores reflecting greater somatic symptom severity. 
Health-related quality of life was assessed using the Medical Outcomes Study Short-
Form 12-item scale (SF-12) from which the Mental Component Summary (MCS) and Physical 
Component Summary (PCS) scores can be derived(19). In addition to the SF-12, 8 items were 
included from the SF-36, which allowed assessment of the SF-36 social functioning, vitality, 
bodily pain, mental health, and current general health scores(20). Scores on these scales range 
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from 0 to 100 with lower scores representing worse health-related quality of life. 
Three disability measures were administered. The Sheehan Disability Scale (SDS) asks 
how much health has interfered with family life, social life, and work over the past month on a 
scale of 0 (not at all) to 10 (unable to carry on any activities)(21). The SDS score is a mean of 
these three items with higher scores reflecting greater disability. Disability days were assessed 
with a single item that asked participants to indicate the number of days during the preceding 4 
weeks that they were either in bed or had to reduce work or usual activities by 50% or more due 
to physical health or emotional problems(10). Work effectiveness was assessed with a single 
item asking how effective the respondent was on his or her job during the past 4 weeks on a 
scale of 0% (not at all effective) to 100% (completely effective). 
Medical co-morbidity was assessed using a checklist that asks about the presence or 
absence of 9 common medical disorders(22).  
Global impression of change was a single item asking patients to rate mood or anxiety 
symptoms compared to the start of the trial as “much worse”, “moderately worse”, “a little 
worse”, “same”, “a little better”, “moderately better”, or “much better”(10). 
2.3 Statistical Analysis 
SAS Version 9.3 was used for all analyses. Correlations between REMIT and PHQ-9 
individual items as well as total scores were calculated. Convergent validity was assessed by 
calculating correlations of the REMIT and PHQ-9 with mental health measures including the SF-
12 MCS, SF-36 mental health, PROMIS depression and anxiety, and the GAD-7. Construct 
validity was assessed by calculating correlations with the Sheehan Disability Index, disability 
days, work effectiveness, PHQ-14 somatization, PROMIS sleep and fatigue, and SF vitality, 
social functioning, and general health.   
To examine the predictive value of REMIT, we conducted three types of analyses.  
    1) We modeled whether baseline scores predicted major depression (MD) status at 6 
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months in the subgroup of 135 patients with MD at baseline. Logistic regression models were 
run with MD status at 6 months (yes or no) as the dependent variable and baseline REMIT and 
PHQ-9 scores entered as predictors individually and then together in the same model. The 
association between other patient characteristics and MD status at 6 months was analyzed to 
determine if models needed to be adjusted for other covariates. The Akaike Information 
Criterion (AIC) was calculated for each model to determine the model with the best fit (i.e., 
lowest AIC value).  
2) We examined whether change in REMIT scores from baseline to 3 months predicted 
MD status at 6 months and, as a sensitivity analysis, three other ways of assessing depression 
improvement: global improvement in mood, PHQ-9 response (score < 10) and PHQ-9 remission 
(score less than 5). Here, we used receiver operating curve analysis to compare the areas 
under the curve (AUC) for the four different ways of assessing depression improvement.   
3) We used repeated measures logistic regression modeling to determine whether 
change in REMIT, PHQ-9, and PHQREMIT (sum of REMIT and PHQ-9) scores predicted global 
improvement in mood over 6 months. Here, we used baseline to 3-month score change to 
predict 3-month global improvement and 3 to 6-month score change to predict 6-month global 
improvement. For this analysis, the full sample of 250 patients with follow-up assessments was 
included for three reasons: 1) all patients in the sample had either depression, anxiety, or both; 
2) the global question asks about change in “low mood or anxiety”; 3) the global outcome 
question is not based upon DSM-V criteria (as is MD status) and thus would be less likely to be 
biased in favor of the PHQ-9. In contrast to the first two analyses which focused on 6-month 
major depression status and for which the appropriate subgroup was those with MD at baseline, 
the third analysis examined improvement in depressive or anxiety symptoms and thus could 
take advantage of the full sample in assessing the predictive value of REMIT.  
3. RESULTS 
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3.1 Study Participants 
A total of 294 participants were enrolled in the study. The overall sample had a mean 
age of 57.4 years (range 25 to 88), and was 87.4% male, 79.3% white, 15.3% black, and 5.4% 
other race. Regarding education, 21% were college graduates, 53% had completed some 
college or trade school, and 26% had only a high school diploma or GED. Major depression was 
present at baseline in 135 participants as determined using the PHQ-9 diagnostic algorithm. For 
purposes of this psychometric analysis, participants from both arms of the trial were collapsed 
into a single dataset.    
3.2 REMIT Psychometric Characteristics 
 REMIT score at baseline for the 294 study participants was a mean (SD) of 9.0 (3.8). 
Baseline scores were normally distributed (Figure S1). Internal reliability was reasonable with a 
Cronbach’s alpha of 0.76, compared to 0.86 and 0.82 in the previous studies(7, 9). The 
standard error of measurement (SEM), calculated as SD x square root of (1 – Cronbach’s 
alpha), was 1.86; one SEM is typically considered the lower statistical bound of a minimally 
important difference (MID). Another estimate of MID is 0.5 SD, which was 1.9 in our sample. 
Taken together, these findings suggest that a 2-point change may represent a reasonable MID 
approximation for the REMIT scale.   
3.3 Comparison of REMIT and PHQ-9 
REMIT and PHQ-9 total scores were only moderately correlated (r = .50), similar to what 
had been found in a previous study comparing the REMIT and PHQ-8(8). This substantiates the 
complementary rather than redundant nature of the REMIT and PHQ-9 scales which focus  
on positive and negative aspects of mood, respectively. Consistent with the overall scale 
findings, individual REMIT and PHQ-9 item correlations also ranged from low to moderate as 
shown in Table 1.  
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Table 1. Pearson correlations between REMIT and PHQ-9 (n = 294) 
REMIT items 
PHQ -9 items PHQ-9 
total 
score 
1 
anhedonia 
2 
depressed 
mood 
3 
sleep 
4 
appetite 
5 
fatigue 
6 
guilt 
7 
concen-
tration 
8 
psycho-
motor 
9 
self- 
harm 
Did you feel happy? .31 .40 .11 .25 .01 .32 .15 .08 .26 .39 
Did you feel 
content? 
.36 .40 .01 .26 .11 .34 .20 .05 .23 .39 
Did you feel in 
control of your 
emotions? 
.18 .19 .11 .21 .09 .33 .21 .13 .07 .32 
Did you bounce 
back when things 
went wrong? 
.15 .28 .05 .16 .00 .28 .18 .15 .18 .30 
Did the future seem 
dark to you? 
.30 .34 -.04 .17 -.05 .36 .19 .14 .32 .37 
REMIT total score .36 .45 .06 .29 .04 .46 .26 .16 .30 .50 
Of the 45 item-item correlations, the median was 0.18, with 11 being 0.30-0.40, 9 being 0.20-
0.29, 15 being 0.10-0.19, and 10 being less than 0.10. Correlations tended to be lower between 
REMIT items and PHQ-9 somatic items such as sleep, appetite, fatigue, and psychomotor 
activity, and tended to be higher when compared to psychological items such as anhedonia, 
mood, or guilt. Spearman correlations were also calculated and were very similar to the Pearson 
correlations, with the exception being that correlations of the 5 REMIT items with the PHQ-9 
fatigue item tended to be higher with the Spearman correlation (median = 0.14, range 0.09 to 
0.15) compared to the Pearson correlation (median = 0.01, range 0.05 to 0.11), suggesting that 
fatigue responses may be more skewed than the other items. 
3.4 Convergent and Construct Validity 
REMIT and PHQ-9 had relatively similar correlations with the other measures of 
convergent and construct validity (Table 2), although the PHQ-9 tended to correlate more 
strongly with measures that included physical symptoms (PHQ-14, PROMIS fatigue and sleep, 
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SF-36 vitality) and measures of disability. The REMIT tended to be more highly correlated with 
several psychological measures such as SF-12 MCS and SF-36 mental health. As expected, 
both REMIT and PHQ-9 correlated poorly with medical comorbidity. 
Table 2. REMIT and PHQ-9 Pearson correlations with other measures (n = 294)* 
Measure REMIT PHQ-9 
Convergent validity   
Mental health (SF-36) -0.76 -0.59 
Depression (PROMIS 8-item) 0.70 0.61 
Mental Component Summary (SF-12) -0.64 -0.57 
Anxiety (PROMIS 8-item) 0.53 0.48 
Anxiety (GAD-7) 0.46 0.52 
Construct validity   
Vitality (SF-36) -0.47 -0.59 
Social functioning (SF-36) -0.45 -0.54 
Sheehan Disability Index 0.41 0.54 
General Health (SF-36) -0.34 -0.31 
Work effectiveness, percent -0.31 -0.38 
Disability days in past 4 weeks 0.29 0.41 
Fatigue (PROMIS 4-item) 0.29 0.55 
Somatization (PHQ-14) 0.27 0.51 
Sleep (PROMIS 4-item) 0.22 0.37 
Medical comorbidity (number of diseases) 0.14 0.12 
* Negative correlations are with measures where higher score is better. 
3.5 Baseline REMIT and PHQ-9 Scores in Predicting Depression Improvement 
Of the 135 patients who had major depression (MD) at baseline, 70 (52%) no longer met 
criteria for MD at 6 months, and 65 (48%) still had MD. Baseline characteristics were similar 
between these two groups (Table S1) except that baseline BPI pain scores were higher in 
patients who continued to meet MD criteria at 6 months (6.6 vs. 5.9). Logistic regression models 
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were used to examine predictors of depression improvement defined as no longer meeting 
criteria for major depression at 6 months. When entered individually into logistic regression 
models, higher (worse) REMIT, PHQ-9, and BPI pain baseline scores each predicted a lower 
odds of depression improvement. When entered in pairwise combinations, REMIT and BPI pain 
(but not PHQ-9) scores remained predictive. When all 3 scores were entered into the same 
model, BPI remained significant (P = .047), REMIT was borderline (P = .07), and PHQ-9 was 
not significant (P = .48). Using the lowest AIC as a criterion, the pairwise model including 
REMIT and BPI pain appeared optimal (Table S2).    
3.6 Change in REMIT Score in Predicting 4 Ways of Measuring Depression Improvement 
To assure that our results were not influenced by the particular method for determining 
depression improvement, we compared 4 different ways of characterizing 6-month depression 
improvement: major depression status (i.e., no longer meeting criteria for MD), global 
improvement, and PHQ-9 response and remission (scores less than 10 and 5, respectively). 
The AUCs for REMIT change were similar across all 4 types of depression outcome (Table 3). 
Table 3. REMIT change at 3-months as a predictor of four ways of defining 6-month 
depression improvement in 135 patients with major depression at baseline. 
Depression Improvement 
outcome at 6 months 
Frequency Percent 
AUC for REMIT change 
at 3 months 
AUC SE 
No major depression 70 51.9 0.592 0.049 
Global improvement in mood 54 40.0 0.595 0.049 
PHQ-9 <10 (response) 34 25.2 0.554 0.056 
PHQ-9 <5 (remission) 16 11.9 0.563 0.066 
 
3.7 Change in Scale Scores Predicting Global Improvement in Mood 
In addition to baseline scores as predictors, we hypothesized that early change in scores 
might also be predictive of depression improvement. Table 4 summarizes results of the 
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repeated measures logistic regression modeling examining change in REMIT and PHQ-9 
scores as well as the composite PHQREMIT score (sum of REMIT and PHQ-9) in predicting 
global improvement in mood over 6 months. Improvement in each of the scores was predictive 
of global improvement. Although odds ratios were relatively similar, REMIT improvement had 
the highest OR and lowest AIC values in models with REMIT alone or with the addition of PHQ-
9.  
Table 4. Improvement in scale scores as predictors of global improvement in mood at 6 
months in the full sample of participants (n=250) 
* Repeated measures logistic regression modeling using baseline to 3 month score change to 
predict 3-month global improvement and 3 to 6-month score change to predict 6-month global 
improvement. 
† An odds ratio greater than 1.0 means that reduction in the scale score increases the odds of 
improvement. For example, an OR of 1.15 for REMIT means that every 1-point reduction in 
REMIT score increases the odds of global improvement at 6 months by 15%. 
 
4. DISCUSSION 
Our study has several important findings. First, the REMIT scale has good internal 
reliability as well as convergent and construct validity. Second, a 2-point change in the REMIT 
score appears to be a reasonable estimate of the minimally important difference. Our 1-SEM 
and 0.5 SD estimates of MID were both 1.9, which correspond to estimates calculated from data 
  Outcome: 6-month Global Mood Improvement  
Model  Predictor (Score Change)* Beta (SE) Odds   
 Ratio† 
95% CI P-value AIC 
Model 1a REMIT improvement .19 (.04) 1.22 1.12 1.31 <.0001 626.23 
Model 1b PHQ-9 improvement .08 (.02) 1.09 1.04 1.14 .0008 642.45 
Model 1c PHQREMIT improvement .10 (.02) 1.10 1.06 1.14 <.0001 626.08 
Model 2 
REMIT improvement .17 (.04) 1.19 1.10 1.29 <.0001 
622.77 
PHQ-9 improvement .06 (.03) 1.06 1.01 1.12 .02 
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in Nease et al (1.7 and 2.3) and Zeng et al (1.2 and 1.4)(7, 9). Third, the REMIT score 
compared to the PHQ-9 score was a stronger predictor of 6-month depression outcomes 
whether using baseline or change scores. 
The REMIT has previously been shown to provide a more robust picture of improvement 
from major depression than tracking DSM symptoms alone. It was originally validated using a 
cross-sectional sample of 1003 primary care patients who were administered the PHQ-8 and 
REMIT. In that study, a moderate correlation (r = 0.46) was found between the PHQ-8 and 
REMIT, similar to the correlation of the PHQ-9 and REMIT (r =0.50) in our study. REMIT was 
also examined in 9855 depressed outpatients in China and compared to Hamilton Rating Scale 
for Depression (HRSD-17) scores at baseline and after 2 and 4 weeks of antidepressant 
treatment. REMIT and HRSD-17 scores were moderately correlated at baseline (r = 0.56), and 
both scores improved with treatment. Although the authors suggested that REMIT scores 
lagged behind HRSD-17 change, the effect size improvements (i.e., change divided by baseline 
SD) in HSRD-17 and REMIT scores were relatively similar at both 2 weeks (1.69 and 1.46, 
respectively) and 4 weeks (2.76 and 2.67). Moreover, the 2- and 4-week changes in REMIT 
score of 4.1 and 7.5 points were large given the 2-point MID estimate. Strengths of our study 
include longer follow-up (6 months compared to the previous cross-sectional and 4-week 
studies), a rich battery of measures to assess convergent and construct validity, and several 
methods for assessing depression outcome.  
Treating depression to remission in measurement-based care entails adjusting therapy 
until patients achieve a desired outcome. Score cut-points on metrics of depression, such as 
below 5 on PHQ-9 or below 7 on HRSD-17 are often used as benchmarks of remission. 
Patients and clinicians have noted that such definitions may not fully capture the patient 
experience, as a number of patients with metric-defined remission do not perceive themselves 
as well(6). This feeling of wellness is better captured in the concept of recovery, which can be 
defined to encompass an improvement of not only the core symptoms of an illness but also 
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quality-of-life and subjective well-being. This is in contrast to defining recovery as sustained 
remission over time(23), which has not proven optimal in predicting sustained improvement or 
decreased risk of relapse(24). REMIT was developed to assess additional facets of depression 
recovery to provide a more robust account of improvement. Our data is consistent with prior 
samples demonstrating that administration of the REMIT as an adjunct to symptom tracking with 
PHQ-9 is a more powerful predictor of depression improvement than PHQ-9 alone. This is 
consistent whether looking at PHQ-9-defined remission or recovery-oriented measures such as 
global improvement ratings. Although other tools have been developed for this purpose(25), the 
brevity of the 5-question REMIT is an advantage in busy clinic settings. 
Our study sample was limited by its relative homogeneity. Patients were enrolled from a 
primary care population of predominantly male veterans who all had comorbid chronic pain. 
Future studies in non-veteran samples with more females, in patients without chronic pain, and 
in individuals cared for in mental health settings will be required to better estimate 
generalizability. Additionally, the AUCs in Table 4 represent modest rather than strong 
differentiation between patients whose depression had improved and those who were the same 
or worse. However, AUCs have fallen in a similar range in other studies using patient-rated 
global improvement (PGIC) as an anchor(26-29) in which AUCs tend to be lower than in studies 
of diagnostic tests for which there is a criterion (“gold”) standard to determine the presence of a 
disease. PGIC requires patients to retrospectively assess change in symptoms compared to a 
prior time point and may be influenced by recall bias as well as the current state of symptoms. 
Thus, the similarity of AUCs when using a PGIC anchor is more salient than their absolute value 
and suggests relative comparability of REMIT change for detecting depression improvement 
measured four different ways. 
Although developed to provide a fuller picture of recovery from major depression, the 
domains assessed by REMIT may also be relevant across a range of mental health conditions 
including anxiety, substance use, and personality disorders, among others. REMIT is comprised 
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of positive psychology items, which are cross-cutting and therefore warrant further research in 
both depressive and non-depressive disorders. Several tools for assessing overall well-being 
have been developed since positive psychology was popularized by Seligman and 
Csikszentmihalyi (30, 31). Originally designed to complement the PHQ-9, REMIT has the 
advantage of adding assessment depth without adding redundancy in settings already utilizing 
PHQ-9 for tracking depression. However, REMIT is not intended to provide a comprehensive 
assessment of overall well-being or flourishing. Tools that assess multiple domains of well-
being, including meaning, purpose, character, social relationships, and financial stability are 
better suited for that purpose(32). Given its promise, further studies are warranted examining 
the sensitivity to change of REMIT in treatment trials and its added value when used in 
conjunction with standard depression measures.  
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